Compare AIXI & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXI | VTAK |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.1M |
| IPO Year | 2023 | 2018 |
| Metric | AIXI | VTAK |
|---|---|---|
| Price | $0.23 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 558.6K | 23.6K |
| Earning Date | 04-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,877,458.00 | $730,000.00 |
| Revenue This Year | $26.84 | $822.86 |
| Revenue Next Year | N/A | $168.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 82.96 |
| 52 Week Low | $0.19 | $1.49 |
| 52 Week High | $5.59 | $15.68 |
| Indicator | AIXI | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.